logo
logo
Delcath Systems, Inc.

Delcath Systems, Inc.

NASDAQ•DCTH
CEO: Mr. Gerard J. Michel MBA, MS
セクター: Healthcare
業種: Medical - Devices
上場日: 2018-05-03
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
連絡先情報
1633 Broadway, 22nd Floor Suite C, New York, NY, 10019, United States
212-489-2100
www.delcath.com
時価総額
$316.46M
PER (TTM)
277.0
31.5
配当利回り
--
52週高値
$18.23
52週安値
$8.12
52週レンジ
10%
順位54Top 78.1%
2.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$20.56M+83.60%
直近4四半期の推移

EPS

$0.02-64.87%
直近4四半期の推移

フリーCF

$4.31M-211.85%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue and Profitability Surge Nine-month revenue reached $64.50M USD, a 192% increase; operating income swung to $2.84M profit.
Strong Operating Cash Flow Operating activities provided $14.27M USD cash, reversing prior period usage of ($17.68M) cash used.
HEPZATO Clinical Trial Success CHOPIN trial met primary endpoint; combination therapy showed 54.7% one-year progression-free survival rate.
Balance Sheet Strengthening Total assets grew to $124.30M USD as of September 30, 2025, up from $76.59M year-end 2024.

リスク要因

Governmental Pricing Program Risks Failure to comply with MDRP/340B reporting risks penalties, sanctions, and termination from Medicaid programs.
Increased R&D Spending Expected R&D expenses increased due to Phase 2 trials; costs expected to rise further to complete trials.
Macroeconomic Uncertainty Heightened High inflation and interest rates threaten ability to access capital on favorable terms or at all.
Customer Concentration Exposure Top four customers accounted for 41.1% of nine-month revenue, indicating concentration risk exposure.

見通し

HEPZATO Expansion Trials Phase 2 trials for mCRC and mBC are commencing, targeting liver-dominant metastatic disease populations.
CHEMOSAT European Reimbursement Expect publication of FOCUS trial data to support increased CHEMOSAT adoption and reimbursement in Europe.
Liquidity Sufficiency Confirmed Current cash, equivalents, and operating cash flow sufficient to support operations for at least 12 months.
Managing Supply Chain Risk Company managing supply chain risk via stockpiled inventory and contracting multiple suppliers for critical components.

同業比較

売上高 (TTM)

agilon health, inc.AGL
$5.89B
+9.9%
Bioventus Inc.BVS
$563.83M
+1.6%
Tactile Systems Technology, Inc.TCMD
$311.51M
+9.3%

粗利益率 (最新四半期)

Semler Scientific, Inc.SMLR
91.5%
+0.1pp
Delcath Systems, Inc.DCTH
87.2%
+1.9pp
RxSight, Inc.RXST
79.9%
+24.3pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
SRDX$614.51M-34.8-15.6%19.2%
TCMD$591.00M33.28.8%6.5%
BVS$542.51M69.35.0%46.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
10.8%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年3月5日
|
EPS:-$0.06
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月4日|
    売上高: $20.56M+83.6%
    |
    EPS: $0.02-64.9%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月6日|
    売上高: $24.16M+211.0%
    |
    EPS: $0.08-115.6%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $19.78M+530.3%
    |
    EPS: $0.03-106.9%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月6日|
    売上高: $37.21M+1701.7%
    |
    EPS: $-0.93+68.5%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月8日|
    売上高: $11.20M+2480.6%
    |
    EPS: $0.06-105.7%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月5日|
    売上高: $7.77M+1468.9%
    |
    EPS: $-0.48-16.2%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月14日|
    売上高: $3.14M+425.8%
    |
    EPS: $-0.45-42.4%
    予想を上回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月26日|
    売上高: $2.07M-24.1%
    |
    EPS: $-2.94+28.7%
    予想を下回る